


## Data Sheet

<b>Product Name:</b>	Doxycycline
<b>Cat. No.:</b>	CS-0009105
<b>CAS No.:</b>	564-25-0
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>24</sub> N <sub>2</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	444.43
<b>Target:</b>	Antibiotic; Bacterial; MMP; Parasite
<b>Pathway:</b>	Anti-infection; Metabolic Enzyme/Protease
<b>Solubility:</b>	DMSO : 100 mg/mL (ultrasonic); H <sub>2</sub> O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)



### BIOLOGICAL ACTIVITY:

Doxycycline, an antibiotic, is an orally active and broad-spectrum metalloproteinase (**MMP**) inhibitor<sup>[1]</sup>. Doxycycline shows antibacterial activity and anti-cancer cell proliferation activity<sup>[1][2][3][4][5]</sup>. *In Vitro*: Doxycycline (0.01-10 µg/mL, 4 d) affects growth of glioma cells only under high concentrations<sup>[2]</sup>.

Doxycycline (0.01-10 µg/mL, 24 h) decreases MT-CO1 protein content with concentrations of 1 µg/mL and higher in SVG cells<sup>[2]</sup>.

Doxycycline (100 ng/mL, 1 µg/mL; 24 h) reduces proliferation of human cell lines<sup>[4]</sup>.

Doxycycline (0-250 µM, 72 h) inhibits cell viability of breast cancer cells<sup>[5]</sup>.

*In Vivo*: Doxycycline (oral gavage; 200 or 800 mg/kg; once daily; 3 months) reduces MMP-9 activity in untreated HT mice in a dose-dependent manner<sup>[3]</sup>.

Doxycycline and Tetracycline (HY-A0107), act systemically after absorption from the upper gastrointestinal tract. The main advantage of Doxycycline over Tetracycline is its longer activity, and it can be taken twice or once a day. The peak concentration of both drugs is similar, but in the case of Doxycycline the time to peak concentration is shorter, and half life is significantly longer<sup>[6]</sup>.

Doxycycline (Dox) is often used as an inducer in molecular biology studies to induce gene expression. In cells or model animals that have constructed tetracycline induced expression systems (Tet-On/Tet-Off systems), the expression of target genes can be precisely controlled by adding or removing Dox<sup>[7][8][9][10]</sup>.

Dose reference for Dox induction<sup>[7][8]</sup>:

(1) Model animal: male Sprague–Dawley rats

Tet regulatory system: 20-3000 ppm of Dox is supplied in diet

(2) Model animal: Cags mice

Tet regulatory system: 625 ppm of Dox is supplied in diet

### References:

[1]. Eusebio Manchado, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. *Nature*. 2016 Jun 30;534(7609):647-51.

[2]. Anna-Luisa Luger, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. *Int J Mol Sci*. 2018 May 17;19(5):1504.

[3]. Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. *J*

Pharmacol Exp Ther. 2011 Jun;337(3):621-7.

- [4]. Ethan Ahler, et al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8(5):e64561.
- [5]. Le Zhang, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745.
- [6]. Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion. 2016;93(2):167-73.
- [7]. Manfredsson FP, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther. 2009 Nov;17(11):1857-67.
- [8]. Redelsperger IM, et al. Stability of Doxycycline in Feed and Water and Minimal Effective Doses in Tetracycline-Inducible Systems. J Am Assoc Lab Anim Sci. 2016;55(4):467-74.
- [9]. Konopka W, et al. Tet system in the brain: transgenic rats and lentiviral vectors approach. Genesis. 2009 Apr;47(4):274-80.
- [10]. Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8.

### CAIndexNames:

2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-

### SMILES:

O=C(N)C(C1=O)=C([C@H]([C@@]2([C@H]([C@@]3([C@H](C4=C(C(O)=CC=C4)C(C3=C([C@@]21O)O)=O)C)[H])O)[H])N(C)C)O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA